Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Molecular Medicine, Faculty of Advanced Biomedical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Molecular Medicine, Faculty of Advanced Biomedical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Biomed Pharmacother. 2017 Dec;96:626-633. doi: 10.1016/j.biopha.2017.08.146. Epub 2017 Oct 13.
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a characterized human oncoprotein that is able to promote cancer cells proliferation, anchorage-independent cell growth and resistance to apoptosis. CIP2A inactivates protein phosphatase 2A (PP2A) which down-regulates Akt (Protein Kinase B) phosphorylation and stabilizes c-Myc (c-Myc oncogene product) in cancer cells. CIP2A has been studied in the most of human malignancies. Here we discuss the role of CIP2A in cancer and give a summary of CIP2A expression in malignancies. Also, where available we indicated the association of CIP2A with the stage of cancers and patients prognosis, explain its localization and the possibility of targeting CIP2A in different cancers.
癌性蛋白磷酸酶 2A 抑制剂（CIP2A）是一种特征性的人类癌蛋白，能够促进癌细胞增殖、非锚定依赖性细胞生长和抗细胞凋亡。CIP2A 使蛋白磷酸酶 2A（PP2A）失活，从而下调 Akt（蛋白激酶 B）磷酸化，并稳定癌细胞中的 c-Myc（c-Myc 癌基因产物）。CIP2A 已在大多数人类恶性肿瘤中进行了研究。在这里，我们讨论了 CIP2A 在癌症中的作用，并对 CIP2A 在恶性肿瘤中的表达进行了总结。此外，在有条件的情况下，我们还指出了 CIP2A 与癌症分期和患者预后的关系，解释了它的定位以及在不同癌症中靶向 CIP2A 的可能性。
